|Description||NMS-P118 is a highly selective Poly(ADP-ribose) Polymerase 1 (PARP-1) inhibitor with excellent ADME, pharmacokinetic profiles and high efficacy in vivo originated by Nerviano Medical Sciences. It was found to be less myelotoxic in vitro than olaparib which is a dual PARP-1/-2 inhibitor. It was in preclinical trials for Breast cancer, but no development had been published yet.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator: Nerviano Medical Sciences|
Talazoparib, also known as BMN-673, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic a...
AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted...
PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.
AY-NH is a selective proteinase-activated receptor 4 (PAR4) receptor agonist peptide. It stimulates aggregation of rat and human platelets in vitro. It reduces ...
3-Aminobenzamide is a competitive PARP inhibitor with Ki of 1.8 μM.
Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. In HCT-116 and HT-29 cell lines, the ability of ABT-888...
Olaparib, also known as AZD-2281 or KU-59436, is a small-molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensiti...
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has poten...